CERS - Cerus inks collaboration with LifeSouth Community Blood Centers

Cerus (CERS) announces an agreement with LifeSouth Community Blood Centers (LifeSouth) to serve as a production partner for INTERCEPT Fibrinogen Complex, the company’s pathogen reduced cryoprecipitated fibrinogen complex product.LifeSouth is the fifth production partner for INTERCEPT Fibrinogen Complex, enabling the initial commercial launch of the product to expand into the state of Florida."The initial market response has been enthusiastic and as we gear up for a nationwide launch in 2022 following anticipated BLA approvals...," Elan Weiner, general manager of Cerus said.

For further details see:

Cerus inks collaboration with LifeSouth Community Blood Centers